This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
ResearchMoz.us includes new market research report, "China Hospital Development and Investment Report, 2014-2017," to its huge collection of research reports.
Albany, NewYork (PRWEB) August 19, 2014
The China Hospital Industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6% in 2011-2013, higher than 2.26% in 2005-2010. The revenue of the China Hospital Industry jumped at a CAGR of 23.6% in 2011-2013, and it is expected to maintain the growth rate of over 20% and hit RMB4.07 trillion in 2017.
At the same time, various social capital flows to the Chinese hospital market by self-establishment, mergers, and acquisitions (including participation in the restructuring of public hospitals), joint ventures, associates and other forms, which boosts the expansion of private hospitals. As of the end of 2013, Chinese private hospitals had accounted for 45.8% of the total Chinese hospitals, increasing by 24.5 percentage points compared with 2006. However, from the point of view of revenue structure, public hospitals still took a dominant position with the proportion of over 90%, but the figure shows a decreasing trend now.
In the private hospital investment boom, specialized hospitals involved with small investment, high returns, and strong market demand have become a hotspot for social capital. Currently, the proportion of Chinese specialized hospitals in private hospitals reaches about 65%. Specialized hospitals in huge demand, such as dental hospitals, ophthalmic hospitals, plastic surgery & cosmetic hospitals, even achieve the profit margins of more than 10%, much higher than the overall level of Chinese hospitals (about 5%).
The enterprises focusing on medicine, including Shanghai Fosun Pharmaceutical, Jinling Pharmaceutical, Inner Mongolia Furui Medical Science, Wuhan Jianmin Pharmaceutical, Yibai Pharmaceutical, China Resources Sanjiu, and Kangmei Pharmaceutical, are actively extending to downstream medical services. Shanghai Fosun Pharmaceutical has stepped in obstetrics & gynecology, tumor and other areas through mergers and acquisitions; its revenue from hospital medical services reached RMB474.6 million in 2013, representing a substantial increase of 215.6% over previous year.
All latest market research report at http://www.researchmoz.us/latest-report.html.
Targeting medium and high-end medical markets, foreign-funded enterprises mainly adopt cooperative operation, equity participation, joint ventures (under the lead of foreign investors) and other approaches to develop business in China, such as Chindex United Family Hospital and Parkway Pantai. United Family Hospital had covered Beijing, Shanghai, Wuxi, Guangzhou and Tianjin by the end of June 2014, and its hospitals in Qingdao and Guangzhou are under construction.
For more information, kindly contact:
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12104422.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.